Pharmacokinetic Profile of Pimavanserin in Patients With Dementia-Related Psychosis and Concomitant Acetylcholinesterase Inhibitor Use: Modeling Data From the Phase 3 HARMONY Study

Authors: Darwish M, Jaworowicz DJ, Owen JS, Brandt T, DeKarske D, Stankovic S
Conference: Alzheimers Association International Conference
Keywords: 5HT2A receptor, AChEI, HARMONY, NCT03325556, pharmacokinetic, pimavanserin, serotonin-modulating
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Introduction

• Pimavanserin is a selective serotonin-modulating agent with inverse agonist/antagonist activity at the 5HT2A receptor, and to a lesser extent at the 5HT2C receptor.
• Pimavanserin’s efficacy and safety were evaluated in patients with
dementia-related psychosis in the phase 3 HARMONY study.
• Polypharmacy is common in elderly patients and many patients with neurodegenerative diseases receive acetylcholinesterase inhibitors (AChEIs).
• Although the clearance mechanisms of AChEIs do not indicate that a drug-drug interaction with pimavanserin is likely, any effects of AChEIs on pimavanserin’s pharmacokinetic (PK) profile have not been previously explored.

By, Mona Darwish, David Jaworowicz, Joel Owen, Teresa Brandt, Daryl DeKarske, Srdjan Stankovic.

Poster presented at the Alzheimer’s Association International Conference (AAIC), July 26–30 , 2021; Virtual.